AI Terminal
ARECOR THERAPEUTICS PLC
Audit Report / Information • Aug 8, 2025
7494_rns_2025-08-08_effd8142-b754-469f-93df-244254304b04.html
Audit Report / Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 5039U
Arecor Therapeutics PLC
08 August 2025
Arecor Therapeutics plc
("Arecor" or the "Company")
CHANGE OF AUDITOR
Cambridge, UK, 8 August 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that following the conclusion of a formal tender process led by the Company's Audit and Risk Committee, the Board has approved the appointment of PKF Littlejohn LLP ("PKF") as the Company's auditor, succeeding Grant Thornton UK LLP ("GT").
GT ceases to hold office as the Company's auditor and has confirmed there are no matters that need to be brought to the attention of the members or creditors of the Company.
PKF will conduct the audit of the Company's financial statements for the financial year ending 31 December 2025. The appointment of PKF as auditor for the following financial year will be subject to approval by the shareholders at the 2026 Annual General Meeting of the Company.
-ENDS-
For more information, please contact:
| Arecor Therapeutics plc | www.arecor.com |
| Dr Sarah Howell, Chief Executive Officer | Tel: +44 (0) 1223 426060 Email: [email protected] |
| David Ellam, Chief Financial Officer | Tel: +44 (0) 1223 426060 Email: [email protected] |
| Singer Capital Markets Advisory LLP (NOMAD and Broker) | |
| Phil Davies, Sam Butcher | Tel: +44 (0) 20 7496 3000 |
| ICR Healthcare | |
| Chris Gardner, David Daley, Lindsey Neville | Tel: +44 (0) 20 3709 5700 Email: [email protected] |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
APPDGGDIUBGDGUR